Next Article in Journal
Exploring the Effects of Pulsed Electric Field Processing Parameters on Polyacetylene Extraction from Carrot Slices
Next Article in Special Issue
Pharmacokinetics and Tissue Distribution Study of Caudatin in Normal and Diethylnitrosamine-Induced Hepatocellular Carcinoma Model Rats
Previous Article in Journal
Rational Drug Design and Synthesis of Molecules Targeting the Angiotensin II Type 1 and Type 2 Receptors
Previous Article in Special Issue
Targeting Carbonic Anhydrase IX Activity and Expression
Article Menu

Export Article

Open AccessReview
Molecules 2015, 20(3), 3898-3941; doi:10.3390/molecules20033898

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

1
RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA 70125, USA
2
Department of Chemistry, Xavier University of Louisiana, New Orleans, LA 70125, USA
3
College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA
*
Authors to whom correspondence should be addressed.
Academic Editor: Jean Jacques Vanden Eynde
Received: 26 December 2014 / Revised: 13 February 2015 / Accepted: 15 February 2015 / Published: 2 March 2015
View Full-Text   |   Download PDF [1114 KB, uploaded 2 March 2015]   |  

Abstract

Histone dacetylases (HDACs) are a group of enzymes that remove acetyl groups from histones and regulate expression of tumor suppressor genes. They are implicated in many human diseases, especially cancer, making them a promising therapeutic target for treatment of the latter by developing a wide variety of inhibitors. HDAC inhibitors interfere with HDAC activity and regulate biological events, such as cell cycle, differentiation and apoptosis in cancer cells. As a result, HDAC inhibitor-based therapies have gained much attention for cancer treatment. To date, the FDA has approved three HDAC inhibitors for cutaneous/peripheral T-cell lymphoma and many more HDAC inhibitors are in different stages of clinical development for the treatment of hematological malignancies as well as solid tumors. In the intensifying efforts to discover new, hopefully more therapeutically efficacious HDAC inhibitors, molecular modeling-based rational drug design has played an important role in identifying potential inhibitors that vary in molecular structures and properties. In this review, we summarize four major structural classes of HDAC inhibitors that are in clinical trials and different computer modeling tools available for their structural modifications as a guide to discover additional HDAC inhibitors with greater therapeutic utility. View Full-Text
Keywords: HDAC inhibitors; cancer; molecular modeling; clinical trials HDAC inhibitors; cancer; molecular modeling; clinical trials
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Mottamal, M.; Zheng, S.; Huang, T.L.; Wang, G. Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents. Molecules 2015, 20, 3898-3941.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top